Wilms Tumor 1 Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Wilms Tumor 1 (WT1) Inhibitor is a pharmaceutical drug that specifically targets the WT1 protein, which is overexpressed in various cancers. The mechanism of action of WT1 inhibitors involves blocking the activity of WT1, thereby inhibiting tumor growth, and promoting cancer cell death. These inhibitors show potential in the treatment of diseases such as acute myeloid leukemia (AML), colorectal cancer, ovarian cancer, and others. According to WHO, AML is the most common acute leukemia in adults, with approximately 18,000 new cases reported in Europe each year. In the United States, AML affects around 20,000 individuals annually, accounting for approximately 1.2% of all new cancer cases. Colorectal cancer is the third most commonly diagnosed cancer worldwide, with 1.8 million cases reported in Europe and 150,000 cases in the United States each year. Ovarian cancer affects around 65,000 women in Europe and 22,000 women in the United States annually, with high mortality rates.

Growth drivers of the WT1 Inhibitor market include increasing awareness about the role of WT1 in various cancers and the need for targeted therapies. Advances in genomics and personalized medicine have highlighted the potential of WT1 inhibitors as precise treatment options for patients with WT1-expressing malignancies. Companies such as Sellas Life Sciences, Sumitomo Pharma, Inovio Marker Therap, Intellia Therap, Medigene, and Eutilex are companies involved in the field of life sciences and therapeutics are pharmaceutical companies operating in the healthcare industry. cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Sumitomo Pharma is currently conducting a clinical trial of the drug WT2725 for the treatment of glioblastoma.

Key Developments:

• In June 2023, SELLAS Life Sciences completed a phase I trial Galinpepimut in Mesothelioma (Combination therapy, Second-line therapy or greater) in the USA.
• In June 2023, Sumitomo Pharma presented updated efficacy and adverse events data from a phase III WIZARD201G trial of Adegramotide/nelatimotide in Glioblastoma at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

Approved Wilms Tumor 1 Inhibitor Molecules

• Zeltherva (galinpepimut-S)
• adegramotide, nelatimotide (DSP-7888)

Wilms Tumor 1 Inhibitor Pipeline Molecules

• INO-5401
• ASP7517
• ATA520
• CMD-602
• MT-601
• Allo WT1-TCR
• CVT-DC-01
• EU210
• MANA-312
• NEXI-001
• RG6007

Clinical Activity and Development of Wilms Tumor 1 Inhibitor

In the Wilms Tumor 1 Inhibitor space, there are very few companies, conducting more than more than 25 clinical trials in this category of drugs. For instance,

• In May 2023, Inovio Pharmaceuticals completed a phase I/II trial of INO 5401 for Glioblastoma (Combination therapy, newly diagnosed) in the USA.
• In June 2023, SELLAS Life Sciences Group released updated efficacy and adverse events data from a phase I trial of Galinpepimut S